Two major Swedish hedge funds have suffered disastrous October results. One of them is Gladiator, managed by Max Mitteregger. The fund had its worst ever monthly result in October, with a -29 percent performance. Year-to-date, Gladiator is down 50 percent, writes Dagens Industri.
One of the main reasons for the poor showing last month is its position in pharmaceutical firm Oncopeptides, a company that has experienced significant stock price drops this year due to issues with clinical studies. Oncopeptides is a portfolio company of life science venture capital firm Healthcap, which invested in it at an early stage, as recently reported by AMWatch.
Already a subscriber? Log in.
Read the whole article
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.Start a free company trial today
Your trial for AMWatch has now started
With your free trial you get:
Full access to all locked articles on AMWatch.
Daily newsletter and ongoing top-newsletters. You can unsubscribe and subscribe to our newsletters anytime.
When your trial period expires
You will not be transferred to a paid subscription.
You will continue to receive our newsletters after the trial period expires. You can unsubscribe at the bottom of each newsletter.